Aug 05, 2024 8:00am EDT Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
Aug 01, 2024 8:00am EDT Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
Jul 10, 2024 8:30am EDT Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
Jun 12, 2024 7:30am EDT Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
May 09, 2024 4:02pm EDT Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
May 06, 2024 3:00am EDT Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
May 02, 2024 7:30am EDT Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
Apr 24, 2024 8:00am EDT Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
Apr 22, 2024 8:12am EDT Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Mar 18, 2024 4:02pm EDT Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
